Qure AI

Detection and localization on imaging is the entire product line. The qXR suite identifies, highlights, and categorizes findings on plain film chest X-rays across six regions of interest including lung, pleura, mediastinum and hila, heart, bone, and hardware, and the qER products cover neurocritical findings on CT. The company sells nothing but algorithms, with nine products spanning X-ray and CT and no hardware or services business underneath.

Cleared as computer assisted detection to be used alongside standard clinical interpretation, meaning the radiologist reads every study and the AI marks regions warranting closer attention. The company frames it explicitly as a frontline support tool for identifying findings that may warrant further workup, and outputs are bounding boxes indicating suspicious regions rather than diagnostic conclusions. Buyers should note that in the emergency and family medicine settings the company targets, the reader may not be a radiologist, which raises the stakes on how findings are presented and acted on.

Among the strongest in the index because the clearance record itself is unusually detailed and the company adds a rare structural commitment. Validation for the most recent clearance included both a standalone performance test and a multi reader multi case clinical study meeting predefined success criteria, which is the higher evidentiary bar for imaging AI. More significant is that qXR-Detect is stated to be the only chest X-ray computer aided detection device cleared with a Predetermined Change Control Plan, meaning the company has pre specified with the FDA how models may be updated. Publishing a change control mechanism addresses the hardest transparency problem in deployed AI, which is silent model drift.

Regulatory validation at exceptional breadth is the core of the case: 26 FDA cleared indications across nine products, exceeding 65 CE certified indications plus other global validations, each requiring performance data reviewed by a regulator. The latest clearance was supported by both standalone and multi reader multi case studies. The company also holds a global health grant to build point of care ultrasound AI, indicating deployment in resource limited settings. What remains thinner in public materials is prospective outcome evidence showing earlier detection changes patient results rather than reader performance.

No published PHI framework or data governance disclosure was located. The company operates across many national jurisdictions with differing health data regimes, which makes stewardship terms a per market question a buyer should resolve rather than assume.

No HIPAA or BAA commitment was located in public materials. The company is India headquartered with US operations and health system customers, so a US buyer should establish business associate terms and confirm where inference and any retained imaging reside.

No SOC 2, HITRUST, or ISO 27001 attestation was located, and no trust center was found. As elsewhere in this index, extensive FDA and CE clearance speaks to device safety and effectiveness rather than the vendor's information security posture.

The deepest regulatory footprint of any vendor in this index. FDA cleared indications total 26 across nine products for X-ray and CT, alongside more than 65 CE certified indications and additional global validations. US clearances span lung nodule identification and quantification, triage and notification for pneumothorax and pleural effusion, multiple neurocritical findings including intracranial hemorrhage, cranial fracture and midline shift, and most recently a six indication chest X-ray detection clearance covering the breadth of findings on plain film. The Predetermined Change Control Plan is the standout element, since it establishes an agreed path for model updates rather than freezing the cleared version or requiring a new submission for each improvement.

No formal governance framework was located, but two structural facts partially substitute. The Predetermined Change Control Plan is a governance mechanism in the most consequential sense, committing the company to a pre agreed process for model change under regulatory oversight. And the global deployment footprint spanning high and low resource settings implies validation across markedly different populations and equipment. What is absent is any published subgroup performance analysis, which matters because chest X-ray AI performance is known to vary with acquisition equipment and patient demographics.

No specific PACS integrations, standards support, or EHR connectivity were located in the materials reviewed. Deployment into emergency department and outpatient reading workflows implies PACS and worklist integration in practice, but nothing is enumerated publicly.

No hosting, tenancy, or data residency disclosure was located. For a company operating across many countries with varying data localization requirements, this is a material gap in published information.

No published pricing. The product portfolio spans nine distinct products across modalities and a large number of separately cleared indications, which typically implies modular per indication or per study pricing, but no structure or rate is disclosed.

Broad and substantiated by clearance record rather than assertion. Modality coverage spans chest X-ray and CT with point of care ultrasound in development, clinical coverage spans pulmonary findings, neurocritical findings, and cardiothoracic indicators, and reader settings explicitly include emergency physicians and family medicine practitioners alongside radiologists. Geographic reach is global, spanning US, EU, and low resource health system deployments. For a pure play imaging AI vendor this is unusually wide.